Enhanced immunogenicity of bortezomib-killed myeloma cells in patients with multiple myeloma. (A) DCs from patients with multiple myeloma (MM) were pulsed with autologous CD138-positive tumor cells killed by γ irradiation, dexamethasone, or bortezomib, matured with LPS, and used for the stimulation of autologous T cells for 2 weeks. IFN-γ producers against unpulsed DCs or DCs pulsed with autologous tumor cells were analyzed by ELISPOT assay. Data shown mean/SD of representative patient of 3 patients tested. *P < .05. (B) Intracellular IFNγ production by autologous tumor cell–specific CD4 and CD8 T cells. T cells were expanded as in panel A, and IFNγ production after stimulation with autologous DCs loaded with killed tumor cells was analyzed by flow cytometry.